Declaration of competing financial interests
From the following article:
Design of effective immunotherapy for human autoimmunity
Marc Feldmann and Lawrence Steinman
Nature 435, 612-619 (2 June 2005)
doi: 10.1038/nature03727
Declaration: Marc Feldman has been a consultant and member of Scientific Advisory Board with multiple companies in the field of autoimmune therapy since 1992. These include Centocor, Inc., Roche Biosciences, Syntex Research, Novartis, Wyeth Research, Amgen, Abbott, Alza Inc., Celgene, Synovis Ltd, Receptor Biologix, Inc., Canji, Inc., Almirall Prodesfarma, Ferring AS, Calyx Therapeutics, Boehringer Ingelheim, Novo Nordisk, Trillium Therapeutics, Inc., Hydra Biosciences and Schering Plough. His laboratory has received grants from Centocor, Wyeth, Roche, Synovis and Celgene. he is a shareholder of Johnson & Johnson, Synovis and Receptor Biologix.
